Interaction of a Standardized Mistletoe (Viscum Album) Preparation with Antitumor Effects of Trastuzumab in Vitro

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2016 Aug 6

PMID 27491866

Citations 15

Authors

U Weissenstein

M Kunz

K Urech

U Regueiro

S Baumgartner

Affiliations

Soon will be listed here.

Abstract

Background: Besides conventional anticancer therapy many breast cancer patients use complementary and alternative medicine (CAM) like the medicinal herb mistletoe (Viscum album L.). To gain more knowledge about possible herb-drug interactions between CAM and conventional anticancer medications, in the present in vitro study we investigated the effect of a standardized mistletoe preparation on the action of Trastuzumab, a drug used for the treatment of Her-2 positive breast cancer.

Methods: The Her-2 positive human breast carcinoma cell line SK-BR-3 was treated with Trastuzumab. Different doses of the drug were combined with Viscum album extract (VAE) in clinically relevant doses. Proliferation, apoptosis, cell cycle and the secretion of vascular endothelial growth factor (VEGF) were analyzed.

Results: No inhibition of antitumor efficacy of Trastuzumab by VAE was detected. VAE and Trastuzumab, either alone or in combination, inhibited proliferation of SK-BR-3 cells in vitro. At higher concentrations VAE induced apoptosis, which was not observed for Trastuzumab. Cells treated with Trastuzumab underwent a G0/G1 cell cycle arrest and cells treated with VAE a G2/M arrest. After application of the two drugs in combination both G0/G1 and G2/M arrest was observed. VEGF secretion of SK-BR-3 cells was significantly inhibited by sole treatment with Trastuzumab or VAE. Combined treatment of Trastuzumab and VAE at clinically relevant doses showed additive inhibitory effects on VEGF secretion.

Conclusions: VAE did not interfere with cytostatic effects of Trastuzumab on SK-BR-3 cells in vitro. Our in vitro results suggest that no risk of safety by herb drug interactions has to be expected from the exposition of cancer cells to Trastuzumab and VAE simultaneously. In contrast, VAE and Trastuzumab seem to exhibit complementary anti-cancer effects in vitro.

Citing Articles

Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation.

Juengel E, Rutz J, Meiborg M, Markowitsch S, Maxeiner S, Grein T Cancers (Basel). 2023; 15(19).

PMID: 37835543 PMC: 10571756. DOI: 10.3390/cancers15194849.

A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells.

Maadi H, Wang Z Cells. 2022; 11(24).

PMID: 36552857 PMC: 9777316. DOI: 10.3390/cells11244093.

Distinct Modulatory Effects of Fever-Range Hyperthermia on the Response of Breast Cancer Cells and Macrophages to Mistletoe ( L.) Extract.

Kozlowski H, Pawlikowska M, Sobocinska J, Jedrzejewski T, Dzialuk A, Wrotek S Pharmaceuticals (Basel). 2021; 14(6).

PMID: 34201348 PMC: 8229697. DOI: 10.3390/ph14060551.

Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells.

Abedin M, Powers K, Aiardo R, Barua D, Barua S Sci Rep. 2021; 11(1):7347.

PMID: 33795712 PMC: 8016985. DOI: 10.1038/s41598-021-86762-6.

Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL).

Wode K, Nordberg J, Kienle G, Elander N, Bernhardson B, Sunde B Trials. 2020; 21(1):783.

PMID: 32917288 PMC: 7488501. DOI: 10.1186/s13063-020-04581-y.

References

Choi Y, Seo H, Choi H, Choi H, Kim S, Shin Y . Induction of Fas-mediated extrinsic apoptosis, p21WAF1-related G2/M cell cycle arrest and ROS generation by costunolide in estrogen receptor-negative breast cancer cells, MDA-MB-231. Mol Cell Biochem. 2011; 363(1-2):119-28. DOI: 10.1007/s11010-011-1164-z. View

Stacey D . Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol. 2003; 15(2):158-63. DOI: 10.1016/s0955-0674(03)00008-5. View

Muthing J, Meisen I, Bulau P, Langer M, Witthohn K, Lentzen H . Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues. Biochemistry. 2004; 43(11):2996-3007. DOI: 10.1021/bi0301892. View

Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Scott J, Panteli V . Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005; 16(4):655-63. DOI: 10.1093/annonc/mdi110. View

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

Klingbeil M, Xavier F, Sardinha L, Severino P, Mathor M, Rodrigues R . Cytotoxic effects of mistletoe (Viscum album L.) in head and neck squamous cell carcinoma cell lines. Oncol Rep. 2013; 30(5):2316-22. DOI: 10.3892/or.2013.2732. View

Sauter E, Nesbit M, Litwin S, Klein-Szanto A, Cheffetz S, Herlyn M . Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res. 1999; 59(19):4876-81. View

Hostanska K, Vuong V, Rocha S, Soengas M, Glanzmann C, Saller R . Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation. Br J Cancer. 2003; 88(11):1785-92. PMC: 2377150. DOI: 10.1038/sj.bjc.6600982. View

Emlet D, Brown K, Kociban D, Pollice A, Smith C, Ong B . Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther. 2007; 6(10):2664-74. DOI: 10.1158/1535-7163.MCT-07-0079. View

10.

Friedel W, Matthes H, Bock P, Zanker K . Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol. 2009; 7(4):137-45. View

11.

Agarwal M, Taylor W, Chernov M, Chernova O, Stark G . The p53 network. J Biol Chem. 1998; 273(1):1-4. DOI: 10.1074/jbc.273.1.1. View

12.

Nahta R . Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol. 2012; 2012:428062. PMC: 3512309. DOI: 10.5402/2012/428062. View

13.

Khil L, Kim W, Lyu S, Park W, Yoon J, Jun H . Mechanisms involved in Korean mistletoe lectin-induced apoptosis of cancer cells. World J Gastroenterol. 2007; 13(20):2811-8. PMC: 4395632. DOI: 10.3748/wjg.v13.i20.2811. View

14.

Sliwkowski M, Lofgren J, Lewis G, Hotaling T, Fendly B, Fox J . Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999; 26(4 Suppl 12):60-70. View

15.

Templeton A, Thurlimann B, Baumann M, Mark M, Stoll S, Schwizer M . Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC Cancer. 2013; 13:153. PMC: 3620944. DOI: 10.1186/1471-2407-13-153. View

16.

Lane H, Beuvink I, Motoyama A, Daly J, Neve R, Hynes N . ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol. 2000; 20(9):3210-23. PMC: 85615. DOI: 10.1128/MCB.20.9.3210-3223.2000. View

17.

Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M . Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999; 18(13):2241-51. DOI: 10.1038/sj.onc.1202526. View

18.

Bartek J, Lukas J . Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003; 3(5):421-9. DOI: 10.1016/s1535-6108(03)00110-7. View

19.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

20.

Bussing A, Raak C, Ostermann T . Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med. 2011; 2012:219402. PMC: 3124023. DOI: 10.1155/2012/219402. View